Systemic Vascular Resistance
Conditions
Brief summary
Obese patients have increased cardiovascular risk and target organ damage (TOD) as compared to people with normal weight. Weight loss reduces cardiovascular risk and TOD. These changes have been associated mainly to changes in inflammatory and pro-atherogenic markers. Office peripheral blood pressure (BP) appears to decrease after bariatric surgery, but information on changes in 24h-ambulatory-BP-monitoring (24h-ABPM) and central-BP(cBP), or about the possible role of renin-angiotensin-aldosterone (RAAS), serotonin(STS) and endocannabinoid(ECS) systems is scarce. Our hypothesis is that the hemodynamic changes mediated by alterations in the RAAS, STS and ECS after weight loss are also responsible for the reduction of TOD.
Interventions
None listed
Sponsors
Parc de Salut Mar
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Patients aged 18 - 65 years, 2. who have medical indication for treatment with bariatric surgery and agreeing to undergo the intervention,with 3. given informed consent
Exclusion criteria
1\. Unmeeting the above Inclusion Criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean changes 24h-aortic systolic-blood pressure (SBP) measured in mmHg | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean changes in peripheral- 24h, daytime and nighttime blood pressure estimates measured in mmHg | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | — |
| Mean change in office blood pressure estimates measured in mmHg | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | — |
| Mean change in arterial stiffness parameters (I) | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | pulse wave velocity measured in m/s |
| Mean change in arterial stiffness parameters (II) | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | augmentation index measured in % |
| Mean change in Left ventricular mass index | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | Left ventricular mass index measured in g/m2 |
| Mean change in Left atrium diameter | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | Left atrium diameter measured in mm |
| Mean change in Ejection fraction | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | Ejection fraction measured in %, |
| Mean changes in aortic- 24h, daytime and nighttime blood pressure estimates others than 24h systolic blood pressure measured in mmHg | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | — |
| Mean change in carotid intima-media thickness measured in mm | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | — |
| Mean change in biochemical parameters measured in mg/dl or mmol/L | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | — |
| Mean change in the components of the renin-angiotensin system | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | renin-angiotensin system: plasma renin activity: ng/mL/h, plasma aldosterone: pg/ml, angiotensinogen: mng/100ml, angiotensin 1-7: pg/ml, ACE: UI/l, ACE-2: UI/I |
| Mean change in the serotonergic system components | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | serotonergic system: 5-HIAA:ng/ml, 5-HT:ng/mL |
| Mean change in the components of the endocannabinoid system | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | endocannabinoid system: Anandamide: nmol/mL, 2-arachidonoylglycerol: mg/ml |
| Mean change in pro-atherosclerotic markers | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | pro-atherosclerotic markers: omentine-1: ng/ml, chemerine: ng/ml, leptin: ng/ml, adiponectine: mcg/ml |
| Mean change in left ventricular remodeling index | From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months. | left ventricular remodeling index, do not have units |
Countries
Spain
Outcome results
None listed